Roth Capital Has Negative Outlook for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Investment analysts at Roth Capital reduced their FY2028 earnings per share estimates for shares of Revelation Biosciences in a research note issued on Thursday, June 5th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $0.84 for the year, down from their previous estimate of $1.00. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($49.33) per share.

Separately, Wall Street Zen cut Revelation Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd.

Revelation Biosciences Stock Performance

NASDAQ REVB opened at $0.84 on Monday. Revelation Biosciences has a fifty-two week low of $0.77 and a fifty-two week high of $60.80. The stock has a 50 day simple moving average of $2.58 and a two-hundred day simple moving average of $4.50. The stock has a market cap of $809,374.40, a P/E ratio of 0.00 and a beta of -0.09.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings data on Thursday, May 8th. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($6.88) by $4.77.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.